Commonly used 3-drug regimen for idiopathic pulmonary fibrosis found harmfulEurekAlert (press release)The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC)…
Heart failure strikes fewer seniors – American Council on Science and Health
Heart failure strikes fewer seniorsAmerican Council on Science and HealthNow, a group of Yale researchers has found that the percentage of senior citizens hospitalized for heart failure has dropped by nearly one third since 1998. The study, published i…
Abbott Touts $4 Billion in New Drug Sales as It Pitches Spinoff – Bloomberg
Abbott Touts $4 Billion in New Drug Sales as It Pitches SpinoffBloombergDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business w…
'No cure to UPA's multiple organ failure' – Daily Pioneer
Tehelka'No cure to UPA's multiple organ failure'Daily PioneerLed by the “weakest Prime Minister ever”, the UPA Government was suffering from a “multiple organ failure” and was showing all symptoms of a “terminal decline”, with i…
Jefferies Analysts Raise Alexion Pharmaceuticals (ALXN) EPS Estimates – LocalizedUSA
Jefferies Analysts Raise Alexion Pharmaceuticals (ALXN) EPS EstimatesLocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeuti…
Ocrelizumab Benefits in MS Maintained to 96 Weeks – Medscape
Ocrelizumab Benefits in MS Maintained to 96 WeeksMedscapeRituximab, an anti-CD20 monoclonal antibody that selectively reduces CD20-positive B-cells, showed "proof of concept" efficacy in MS in phase 1 and 2 investigations, they say. Ocrelizum…
Abbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1B – Wall Street Journal
USA TodayAbbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1BWall Street JournalHowever, several of these drugs, including daclizumab, may not make it to market until around 2015, assuming successful clinical trials and regulatory appro…
Heart failure burden 'will rise in tandem with life expectancy' – Zenopa
Heart failure burden 'will rise in tandem with life expectancy'ZenopaThe prevalence of heart failure cases in the UK is likely to increase as a result of rising life expectancy rates, according to the British Heart Foundation (BHF). New figures…
JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen … – LocalizedUSA
JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interfero…
IncellDx CEO Applauds New Cancer Screening Recommendations – MarketWatch (press release)
IncellDx CEO Applauds New Cancer Screening RecommendationsMarketWatch (press release)IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AI…